Denali Therapeutics Inc
DNLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.81B
Close$
$0.96
95.8% downside
Current Fair Value
95.8% downsideOvervalued by 95.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.81 Billion |
|---|---|
| Enterprise Value | $3.64 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | 1 |
| Outstanding Shares | 187,314,501 |
Return
| Return on Equity | -61.24% |
|---|---|
| Return on Assets | -44.17% |
| Return on Invested Capital | -49.99% |
Valuation & Multiples
| P/E Ratio | -8.45 |
|---|---|
| PEG | -305.44 |
| Price to Sales | - |
| Price to Book Ratio | 5.7 |
| Enterprise Value to Revenue | 1008.6 |
| Enterprise Value to EBIT | -6.81 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$2.15 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$12.23 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9417▲ 44.83% |
|---|---|
| Total Calls | 619,100▲ 6.65% |
| Total Puts | 583,000▲ 103.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.39%▲ 2.38% |
|---|---|
| Total Invested | $4.18B▲ 48.13% |
| Investors Holding | 301▲ 19.00% |
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts